Versius

CMR Surgical (founded 2014, Cambridge, UK; private) makes Versius, the genuine challenger among surgical-robot startups and the one that has clearly crossed the regulatory gating event. Versius is a modular multi-arm teleoperated soft-tissue robot that is heavily software-driven, capturing telematic, video, and outcome data. It received US FDA De Novo marketing authorization in October 2024, the first such authorization for a multi-port soft-tissue general-surgery robot, followed by an FDA 510(k) clearance for the next-generation Versius Plus on December 18, 2025 with US commercialization on track for 2026, and a pending gynecology 510(k) submitted on April 29, 2026; it has long been CE-marked and commercial across Europe, Latin America, the Africa-Middle-East region, and Australia, with more than 40,000 procedures completed outside the US by company reporting. The registry records it at commercial maturity with an active lifecycle. An important current-state correction: the 2021 roughly $3 billion SoftBank-led valuation story is frozen in time, the company went through real restructuring in 2023 with about 350 redundancies, and it was recapitalized with more than $200 million in April 2025, while reported figures of a roughly $3.1 billion 2025 valuation and a potential $4 billion sale are rumor-tier aggregator claims that are not registered. On AI substance the shipped reality is a data-capture and analytics ecosystem with the surgeon in full control; the physical-AI framing is forward-looking, anchored in a March 2026 NVIDIA IGX Thor partnership to evaluate AI for a future Versius, with no autonomous or AI-assisted intraoperative feature cleared or shipped.

Versius is listed at $750,000 to $1,000,000 on the DEPLOY registry. This is an analyst estimate, not an official price.

Yes. Versius is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Not verified as fully autonomous. Versius's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.

Versius is made by CMR Surgical, based in Cambridge, United Kingdom, founded in 2014.

5 verified deployments of Versius are on the DEPLOY registry, including at United States (multiple hotel chains), Italy, Australia.

Versius is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.

Versius has 3 regulatory records on the DEPLOY registry: FDA 510(k) clearance, cleared; FDA De Novo authorization, cleared; FDA De Novo authorization (DEN230078), granted. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable surgical robots to Versius include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

Versius and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. Versius has 5 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Versius ranks in roughly the top 14% of surgical models tracked by the registry.

Versius is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Versius has 5 active incidents on record in the DEPLOY registry. 1 recall and 4 incidents on record (1 serious, 1 moderate, 3 minor). Most recent: Jul 2026. Retracted incidents are excluded from this count.

The CMR Versius is a modular and portable surgical robot designed to make minimal access surgery more accessible. A da Vinci system costs $1.5M to $2.5M depending on configuration, plus annual maintenance. Versius is designed to be more portable and affordable than da Vinci, with a modular architecture that fits in smaller operating rooms.